This trial is evaluating whether Pentosan Polysulfate Sodium will improve 1 primary outcome, 36 secondary outcomes, and 16 other outcomes in patients with Osteoarthritis, Knee. Measurement will happen over the course of Baseline to Day 56.
This trial requires 938 total participants across 4 different treatment groups
This trial involves 4 different treatments. Pentosan Polysulfate Sodium is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
Knee replacements are rarely used to treat only knee pain. Other treatments include conservative treatments such as NSAIDs and pain management (including non-opioid alternatives and physical therapy) or oral, intra-articular, or extra-articular modalities, such as a variety of medications and surgery. Non-steroidal anti-inflammatory drugs are recommended over paracetamol for low-quality evidence as initial treatments for osteoarthritis of the knee. Other non-opioid medications are only recommended if NSAIDs do not provide sufficient relief in certain types of osteoarthritis.
around 25 million people in the United States have [osteoarthritis](https://www.withpower.com/clinical-trials/osteoarthritis) of the knee, of which around 11% has clinical knee OA (symptoms and/or signs) on radiography.
Obesity, age, body weight, gender, knee joint effusion, and knee osteophyte formation may affect knee cartilage destruction, which is the main cause of knee OA. Knee joint effusion may also play an important role in knee cartilage destruction in obese people with knee OA.
Knee OA, not knee joint space narrowing (KSW), can be cured following arthroscopic lavage with 1% lidocaine solution or 1.2% lidocaine gel. It is essential to know that knee joint space narrowing (KSW) cannot be cured to prevent further knee OA.
The knee is a joint that sits sideways on the thigh. It is important to pay attention to the position of the knee when walking or doing daily activities. Damage to the knee knee can result in osteoarthritis and this can cause pain, stiffness and limitation of joint movement. This article helps us to understand osteoarthritis and helps us to detect early signs and signs of its onset. Osteoarthritis also can be treated and this article helps us to do it.
All five of the signs of knee osteoarthritis were common and were present in every patient at some stage of their disease. The most common signs were stiffness (74%) and joint space narrowing or bowing (45%). The knee should be assessed by palpation, range of motion or in the squatting position, so that symptoms can be detected early and treatment adjusted accordingly. Since all of these signs are present early in untreated knee osteoarthritis, early diagnosis is an important factor in the management of the disease.
A recent trial has revealed that PPSS shows positive effects on a broad spectrum of illnesses such as rheumatoid joints, psoriasis, and other inflammatory diseases.\nTo date, there has been little research or clinical study, however, involving the use of PPSS in the treatment of osteoarthritis.\nAs of today, there are no clear indications for the use of PPSS in treatment of osteoarthritis. However, there is still a lack of a large-randomized, double-blind, placebo-controlled study that is designed to examine the use of PPSS over time in regard to disease progression in osteoarthritis of the knee.
Osteoarthritis often begins in one joint(ies) and spreads quickly between adjacent joints. Osteoarthritis causes pain, stiffness, and swelling in the knee. [Osteoarthritis.org] This disease and its symptoms are common among older adults, but there are no studies done specifically investigating the prevalence of this disease in a younger group. The average age when the knee begins to show signs of osteoarthritis is about age 65.\n\nThe [U.S government.] Centers for Disease Control and Prevention (CDC) is responsible for reporting and investigating health problems in the U.S.
SPS is seldom the sole OA treatment being used. Physicians frequently use SPS with NSAIDs, bisphosphonates, or corticosteroids, and often with additional anti-inflammatory drugs. In some respects, SPS acts as an adjunct because in combination with NSAIDs it may slow the progression of disease and improve pain relief.
PPS does not seem effective in improving the pain of chronic hip OA for 2 months. We were unable to observe benefits to a greater extent than placebo after 4 months of treatment.
We found that moderate to severe knee OA has a major influence on the QoL and SF-12 in women, but not in men. Since moderate to severe knee OA was not associated with greater radiographical joint space narrowing, more research is required to confirm whether moderate to severe knee OA will lead to the development of patellofemoral pain syndrome. In addition to severity criteria, osteophytestes should be used more often as an indicator of disease severity.
The most common side effects in this trial were nausea (5.6% of patients) and diarrhea (4.5% of patients). Numbness, dizziness, and increased appetite were also fairly common.